Equities

Codexis Inc

Codexis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.02
  • Today's Change-0.04 / -0.99%
  • Shares traded421.27k
  • 1 Year change+142.17%
  • Beta2.1076
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments65114117
Total Receivables, Net204138
Total Inventory2.692.031.16
Prepaid expenses5.225.495.70
Other current assets, total0.520.520.58
Total current assets93163162
Property, plant & equipment, net296265
Goodwill, net2.463.243.24
Intangibles, net------
Long term investments9.702114
Note receivable - long term------
Other long term assets1.250.350.28
Total assets137250246
LIABILITIES
Accounts payable5.953.253.00
Accrued expenses203228
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total10142.59
Total current liabilities364933
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total145749
Total liabilities5010682
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital584566552
Retained earnings (accumulated deficit)(498)(421)(388)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity87145164
Total liabilities & shareholders' equity137250246
Total common shares outstanding706665
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.